Claim evaluation bench
The Frequency Desk
Royal Raymond Rife (1888–1971) was a real San Diego inventor. Institutional collections document his microscopes; they do not independently confirm the extraordinary optical performance later writers attributed to them. The 1934 cancer-trial results lack an auditable primary clinical file. Mortal Oscillatory Rates remain a historical hypothesis, not a reproduced clinical mechanism. FDA-authorized electromagnetic oncology devices use different fields, indications, and evidence and do not validate consumer Rife machines or attributed frequency lists. This desk is historical evaluation, not medical advice.
Not medical advice. Not a device guide.
This page is historical evaluation of claims. It is not a diagnosis, a protocol, or a recommendation to use frequency devices instead of qualified care. Rife-style machines and attributed frequency lists are not FDA-approved treatments.
The desk will not tell you which hertz to run, how long to sit in front of a machine, or how to build one. Construction and treatment instructions would be dual-use medical guidance; they are out of scope.
Rife Frequency Guide · evaluation only
Place one claim. Read the trace.
Each folder is a claim as it is commonly told. The CRT shows the surviving record, an evidence grade, and sources. All six evaluations are in the HTML; JavaScript only advances the selected folder.
Claim recorded; performance not reproduced
Did Rife’s microscope see living viruses at 60,000×?
Common tell
Later retellings say the Universal Microscope reached 60,000× magnification with 31,000-diameter resolution and showed living filterable organisms in characteristic colors — work no conventional light microscope could match.
Surviving record
A 1944 Smithsonian annual-report article recorded those extraordinary optical claims; it is not an independent performance test. Science Museum Group holds Prismatic Compound Microscope No. 5 (inv. 1990-667). Bracegirdle’s 2003 Quekett examination of a surviving Rife microscope found resolution “extremely poor.” Existence of an instrument is not confirmation of the claimed optics.
GradeClaim recorded; performance not reproducedPrimary publication and a surviving object exist. Later optical testing did not recover the advertised resolution. Missing parts or alignment may explain some of the gap; they do not close it.
This card does not reconstruct prism trains, heterodyning setups, or any method for observing pathogens.
- Museum objectScience Museum Group, inv. 1990-667
- Institutional recordSmithsonian Institution Archives image record
- Later examinationBracegirdle, Quekett Journal of Microscopy 39:459–473 (2003)
Later account; no auditable clinical file
Did the 1934 trial cure 16 terminal cancer patients?
Common tell
The popular story says a USC Special Medical Research Committee treated sixteen terminal cancer patients in La Jolla in summer 1934 and that all sixteen recovered — often told as a signed, 100% clinical success.
Surviving record
Contemporary coverage and later participant accounts refer to committee work headed by Dr. Milbank Johnson. This project holds no auditable primary clinical file: no surviving case charts, no peer-reviewed trial paper, no independent outcome table. Supportive books (notably Lynes, 1987) narrate complete recovery; that is a later secondary account, not a recovered study file. Missing records limit conclusions. They do not prove a cure, and they do not by themselves prove that a file was destroyed.
GradeLater account; no auditable clinical fileThe trial is discussed in the period record. The specific 16-of-16 outcome is not established from a primary clinical archive available here.
This card does not list exposure times, treatment intervals, or any schedule someone could follow.
Historical hypothesis, not a shown mechanism
Does every pathogen have a Mortal Oscillatory Rate?
Common tell
Supporters treat MOR as a biological law: each microorganism has a unique destructive frequency, analogized to shattering a wine glass, and Rife catalogued those rates.
Surviving record
MOR is Rife’s historical hypothesis for how his Beam Ray instruments were supposed to work. A wine-glass analogy describes mechanical resonance in glass; it does not establish selective destruction of organisms in living tissue. Independent researchers have not reproduced a clinical organism-frequency catalog. Attributed lists that circulate today are not a validated mechanism.
GradeHistorical hypothesis, not a shown mechanismThe term is part of the documentary story. It is not a demonstrated, general medical principle.
This card does not publish a pathogen-to-frequency lookup for use on a person or a device.
- Internal guideSite science: MOR principle and limits
- Internal guideAttributed lists kept as historical dataset
Distinct modern evidence; does not transfer
Do TTFields or TheraBionic prove that Rife was right?
Common tell
Marketing and forum posts often treat FDA-authorized electromagnetic cancer devices as belated proof of Rife’s frequencies, microscope, and consumer “Rife machines.”
Surviving record
Tumor Treating Fields (Optune and related PMA devices) and TheraBionic’s September 26, 2023 Humanitarian Device Exemption are real, device-specific regulatory actions. They use defined field parameters, indications, and evidence packages that differ from claimed Mortal Oscillatory Rates. Those decisions support those devices and uses only. Vocabulary overlap (“frequency,” “fields”) is not a shared mechanism and does not validate attributed Rife lists.
GradeDistinct modern evidence; does not transferCite the FDA records for those products. Do not cite them as retrospective validation of Rife.
This card does not compare output circuits, recommend a consumer device, or treat an HDE as a general cancer approval.
- Primary regulatoryFDA Optune PMA supplement summary (P100034)
- Primary regulatoryFDA TheraBionic HDE summary (H220001, 2023)
Legal events documented; campaign not established
Did the AMA erase a proven cancer cure?
Common tell
A coordinated campaign — often centered on Morris Fishbein — is said to have bought, buried, or burned Rife’s work after a successful trial, leaving only a suppression story.
Surviving record
Documented layer: the 1939 Beam Rays civil dispute, later inactivity of the company, John Crane’s 1961 prosecution, and Rife’s impoverished later life. Disputed layer: bribery of Hoyland, Fishbein personally directing a Rife takedown, arson, and a successful erasure of a proven cure. Benedict Fitzgerald’s 1953 staff statement, placed in the Congressional Record, criticizes institutional treatment of some proposed cancer remedies; it does not name Rife and is not a clinical validation. Legal events are not proof of efficacy or of a single conspiracy.
GradeLegal events documented; campaign not establishedCourt and institutional records can be cited. The full suppression narrative cannot be cited as settled fact from this archive.
This card does not treat a lawsuit, a prison sentence, or a missing file as evidence that a frequency device works.
- Internal guideSite suppression page: events vs allegations
- Internal guideFitzgerald statement context (Congressional Record, 1953)
Later compilation, not a treatment protocol
Are circulating frequency lists Rife’s original protocols?
Common tell
Downloadable charts and the Consolidated Annotated Frequency List are often sold or shared as “Rife frequencies” for named diseases — as if they were the 1930s clinical catalog.
Surviving record
Two historical sets are in circulation. Accounts of 1930s Beam Ray work describe higher audio-range figures generated as sidebands on a radio-frequency carrier. Crane-era devices in the 1950s–60s used much lower audio figures. Most modern compilations, including CAFL-style lists, derive from that later lineage. The CAFL itself has been described by compilers as not well tested. None of these tables is an FDA-approved protocol, and this desk does not offer them as treatment.
GradeLater compilation, not a treatment protocolProvenance is mixed and often Crane-era. Disease labels on a spreadsheet are not evidence of safety or effect.
This card does not print a condition-to-hertz table, a session length, or instructions for running a machine.
- Internal guideSite frequencies: attributed lists, not instructions
- Primary patentU.S. Patent 1,727,618 (Rife microscope patent)
How this desk grades a claim
- Object versus performance. A museum microscope or a patent shows that hardware existed. It does not show that the advertised resolution or biological effect was obtained.
- Primary clinical file versus later story. If case charts and a trial paper are missing, a complete-cure narrative stays a later account.
- Legal event versus campaign. Lawsuits and prosecutions can be documented without proving that a suppressed cure existed.
- Modern device versus Rife vocabulary. FDA records attach to named products. They do not travel backward onto attributed frequency lists.
- List versus protocol. Historical hertz tables are archived elsewhere on this site with explicit safety boundaries. This desk will not convert them into advice.
Questions this desk answers
Read the archive next
The desk is the evaluation. The rest of the site holds the chronology, instrument claims, attributed lists, and legal record — still without treatment instructions.